))
Episodes 46: Spiro Rombotis- CEO at Cyclacel
Manage episode 386335424 series 3526490
Innhold levert av Vial. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Vial eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
We’re thrilled to share our enlightening exchange with Spiro Rombotis, the seasoned CEO of Cyclacel. He peels back the curtain on the breakthrough discovery of B53, a commonly mutated gene in cancer patients, and the inspiring success of FADRA, their lead drug in clinical trials. Furthermore, Spiro delves into the highs and lows faced by Cyclacel, including the triumphant moment a patient was declared cancer-free thanks to their groundbreaking drug.
First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.
Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.
🎧 Stay in the Loop!
For the latest news and updates, visit our website: https://vial.com
Follow us on social media for real-time insights:
Twitter: https://twitter.com/VialTrials
LinkedIn: https://www.linkedin.com/company/vialtrials
Kapitler
1. Episodes 46: Spiro Rombotis- CEO at Cyclacel (00:00:00)
2. Cancer Research and Drug Advancements (00:00:06)
3. Biotech and Clinical Research Opportunities (00:14:03)
4. Health Patient Advice for Success (00:20:50)
62 episoder
Del
